Biocoat, Incorporated

Biocoat, Incorporated is a specialized manufacturer focused on hydrophilic coatings for medical devices, enhancing product performance and safety in critical healthcare applications. Founded in 1991, Biocoat, Incorporated is headquartered in Horsham, US. The company develops advanced hydrophilic coatings and has engaged in two key funding deals, the latest in November 2022. Biocoat was established by a team with a vision for improving medical technology, though specific details about the founders are not available.

Biocoat Incorporated specializes in the development, manufacturing, and application of advanced hydrophilic coatings, primarily focusing on medical devices. The company's flagship product, the HYDAK® technology, is engineered to enhance lubricity, durability, and reduce particulates, thus ensuring optimal performance in various medical applications. These coatings are custom-designed to meet specific client requirements, catering to sectors such as neurovascular, cardiovascular, and urology markets, among others. Biocoat’s products serve a diverse client base that includes medical device manufacturers globally, particularly in North America, Europe, and Asia.

The company also offers coating services and custom polymer synthesis, further solidifying its position as a full-service leader in hydrophilic coatings for medical devices. Biocoat's revenue is generated through a combination of direct sales and partnerships with medical device manufacturers. The company engages in B2B transactions, providing hydrophilic coatings and related services under structured agreements tailored to the needs of its clients. This includes the sale of coatings such as HYDAK® UV, which has gained FDA 510(k) clearance for use in approved medical devices.

The pricing structure is typically based on the complexity and scale of coating requirements, with customers often entering into contracts that may involve multiple units or ongoing service agreements. Additionally, the strategic acquisition of companies like Chempilots has expanded Biocoat's offerings, enabling it to provide a broader range of solutions to its clientele. In November 2022, GTCR invested in Biocoat, Incorporated to support the company's expansion of its biomaterial product lines. The company plans to launch new products focused on enhancing their coating technologies and expanding into new markets, particularly in Europe and Asia, by 2024.

The recent funding will be utilized to facilitate these initiatives and enhance operational capabilities.